Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer

A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Case Studies Colorectal Cancer Oncology Journal Source Type: news

Related Links:

Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionHAI oxaliplatin combined with capecitabine +/ − bevacizumab was well-tolerated and was associated with favorable outcomes in selected patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionsPSE can be considered as a treatment option for HST.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
ConclusionSecond-generation CS-PHP seems to be effective and tolerable. Patient selection based on tumor volume and entity is of importance. Particularly, patients with OM and hepatobiliary tumors represent promising candidates for CS-PHP.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Abstract Purpose Lenalidomide has synergistic anticancer effects when used with chemotherapy. We conducted a phase I study of lenalidomide in combination with FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) in patients with advanced cancer. Methods A “3 + 3” study design was used. Lenalidomide was given orally on days 1–14, oxaliplatin and leucovorin were given intravenously on day 1, and 5-fluorouracil was given as a continuous infusion on days 1–2. The dose escalation phase of the study was followed by an expansio...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Background: MRX34 is a liposomal nanoparticle formulation with an encapsulated mimic of the naturally occurring microRNA-34 (miR-34), which is lost or expressed at reduced levels in many tumors. miR-34 inhibits key oncogenic pathways by repressing multiple important oncogenes including BCL2, E2F3, HDAC1, MET, MEK1, CDK4/6, PDGFR-a/β, SIRT1, WNT1/3, NOTCH-1, β-catenin, CD44, Nanog and AXL. miR-34 also represses the expression of PD-L1 and DGK, thereby possibly triggering an anti-tumor immune response and cancer cell death. A multicenter Phase 1 clinical trial of MRX34 is being conducted in patients with advanced m...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Clinical Trials: Poster Presentations - Proffered Abstracts Source Type: research
ConclusionIn Monotherapy, AM0010 has a well-tolerated safety profile and leads to sustained and systemic immune stimulation. The pharmacodynamics and clinical activity observed support the ongoing monotherapy expansions and combination regimens with checkpoint inhibitors as well as cytotoxic chemotherapies.Trial registration: www.clinicaltrials.gov NCT02009449Citation Format: Jeffrey R. Infante, Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Deborah J. Wong, Gerald S. Falchook, Manish Patel, Shubham Pant, Melinda Whiteside, Johanna C. Bendell, Todd M. Bauer, Filip Janku, Milind Javle, Rivka Colen, Ni...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Tumor Immunology Targets: Poster Presentations - Proffered Abstracts Source Type: research
Discussion The MTD of BKM120 in combination with standard doses of mFOLFOX6 was 40 mg daily, which is well below the 100 mg daily dose proven effective and tolerable both as a single agent and in combination with other chemotherapeutics. In addition, the regimen of BKM120 with mFOLFOX6 in patients with refractory solid tumors resulted in increased toxicity than would be expected from either the PI3K inhibitor or the chemotherapy backbone alone.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONSThe recommended dose of PDX was 148 mg/m2. A subset of heavily pretreated patients had PFS durations of ≥6 months with this regimen. Cancer 2015. © 2015 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Pancreas | Pancreatic Cancer | Study | Thrombocytopenia | Xeloda